Ibj.com4h
Lilly’s Omvoh part of company’s expansion into inflammatory bowel disease treatment
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Pharm Exec7h
Treating Disruptive Symptom’s in Crohn’s Patients: Q&A with Mark Genovese, MD
Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...
gastroenterologyadvisor3h
Severe Histologic Disease Activity in UC Raises Risk of Biologic-Associated Colectomy
Baseline histologic activity predicted colectomy risk in ulcerative colitis treated with biologics, independent of clinical or endoscopic factors.
gastroenterologyadvisor3h
FDA Approves New Vial Sizes for GVHD Treatment Niktimvo
The FDA has approved 2 additional vial sizes of Niktimvo™ (axatilimab-csfr), 9mg/0.18mL and 22mg/0.44mL, in addition to the 50mg/mL size.